BACKGROUND: Several treatments are available to reduce the risk of fragility fractures associated with osteoporosis. The choice of treatment requires knowledge of patients' values and preferences. The aim of the present study was to summarize what is known about the values and preferences relevant to the management of osteoporosis in women. METHODS: We conducted a comprehensive search of several databases for studies reported in any language that had included women who had already started or were about to start any pharmacological therapy for osteoporosis. Pairs of reviewers independently selected the studies and extracted the data. The results were synthesized narratively. RESULTS: We included 26 studies reporting on 15,348 women (mean age, 66 years). The women considered the effectiveness and adverse events equally, followed by the convenience of taking the drug and its effect on daily routine (less frequent dosing was preferred, the oral route was preferred, and the injectable route was preferred over oral if given less frequently). The treatment cost and duration were less important factors for decision making. Fear of breast cancer and fear of resuming uterine bleeding were common reasons for not choosing estrogen therapy. Calcium and vitamin D were viewed as safe and natural. Across the studies, the preferences were not affected by age, previous drug exposure, or employment status. CONCLUSIONS: Women starting osteoporosis medications value effectiveness and side effects equally and prefer medications given less frequently. Injectable drugs appear acceptable if given less frequently. More research on patient values and preferences is needed to guide decision making in osteoporosis.
BACKGROUND: Several treatments are available to reduce the risk of fragility fractures associated with osteoporosis. The choice of treatment requires knowledge of patients' values and preferences. The aim of the present study was to summarize what is known about the values and preferences relevant to the management of osteoporosis in women. METHODS: We conducted a comprehensive search of several databases for studies reported in any language that had included women who had already started or were about to start any pharmacological therapy for osteoporosis. Pairs of reviewers independently selected the studies and extracted the data. The results were synthesized narratively. RESULTS: We included 26 studies reporting on 15,348 women (mean age, 66 years). The women considered the effectiveness and adverse events equally, followed by the convenience of taking the drug and its effect on daily routine (less frequent dosing was preferred, the oral route was preferred, and the injectable route was preferred over oral if given less frequently). The treatment cost and duration were less important factors for decision making. Fear of breast cancer and fear of resuming uterine bleeding were common reasons for not choosing estrogen therapy. Calcium and vitamin D were viewed as safe and natural. Across the studies, the preferences were not affected by age, previous drug exposure, or employment status. CONCLUSIONS:Women starting osteoporosis medications value effectiveness and side effects equally and prefer medications given less frequently. Injectable drugs appear acceptable if given less frequently. More research on patient values and preferences is needed to guide decision making in osteoporosis.
Authors: Jeffrey C Andrews; Holger J Schünemann; Andrew D Oxman; Kevin Pottie; Joerg J Meerpohl; Pablo Alonso Coello; David Rind; Victor M Montori; Juan Pablo Brito; Susan Norris; Mahmoud Elbarbary; Piet Post; Mona Nasser; Vijay Shukla; Roman Jaeschke; Jan Brozek; Ben Djulbegovic; Gordon Guyatt Journal: J Clin Epidemiol Date: 2013-04-06 Impact factor: 6.437
Authors: Victor M Montori; Nilay D Shah; Laurie J Pencille; Megan E Branda; Holly K Van Houten; Brian A Swiglo; Rebecca L Kesman; Sidna M Tulledge-Scheitel; Thomas M Jaeger; Ruth E Johnson; Gregory A Bartel; L Joseph Melton; Robert A Wermers Journal: Am J Med Date: 2011-06 Impact factor: 4.965
Authors: Mohammad Hassan Murad; Matthew T Drake; Rebecca J Mullan; Karen F Mauck; Louise M Stuart; Melanie A Lane; Nisrin O Abu Elnour; Patricia J Erwin; Ahmad Hazem; Milo A Puhan; Tianjing Li; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2012-06 Impact factor: 5.958
Authors: M S LeBoff; S L Greenspan; K L Insogna; E M Lewiecki; K G Saag; A J Singer; E S Siris Journal: Osteoporos Int Date: 2022-04-28 Impact factor: 5.071
Authors: Elizabeth M Curtis; Jean-Yves Reginster; Nasser Al-Daghri; Emmanuel Biver; Maria Luisa Brandi; Etienne Cavalier; Peyman Hadji; Philippe Halbout; Nicholas C Harvey; Mickaël Hiligsmann; M Kassim Javaid; John A Kanis; Jean-Marc Kaufman; Olivier Lamy; Radmila Matijevic; Adolfo Diez Perez; Régis Pierre Radermecker; Mário Miguel Rosa; Thierry Thomas; Friederike Thomasius; Mila Vlaskovska; René Rizzoli; Cyrus Cooper Journal: Aging Clin Exp Res Date: 2022-03-24 Impact factor: 4.481